Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke?

Cerebrovascular Diseases

Volumn 30, Issue 5, 2010, Pages 508-513

  Ibrahim, Mohamed M ^a   Sebastian, Joseph ^a   Hussain, Muhammad ^a,f   Al Hussain, Fawaz ^a   Uchino, Ken ^d   Molina, Carlos ^c   Khan, Khurshid ^a   Demchuk, Andrew M ^b,c   Alexandrov, Andrei V ^e   Saqqur, Maher ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ALABAMA HOSPITAL   (United States)

^f KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antiplatelet; Recanalization; rt PA; Stroke, outcome; Transcranial Doppler

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALTEPLASE; CLOPIDOGREL; DIPYRIDAMOLE; WARFARIN;

ACUTE DISEASE; AGED; ARTERY OCCLUSION; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CONTROLLED STUDY; DIABETES MELLITUS; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RECANALIZATION; RETROSPECTIVE STUDY; STROKE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; WARFARIN;

EID: 77956854711     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319029     Document Type: Article

References (19)

1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
2. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA: Intravenous tissuetype plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283: 1145-1150.
3. Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M, Levine SR: Predictors of good outcome after intravenous TPA for acute ischemic stroke. Neurology 2001; 57: 474-480.
4. Molina CA, Alexandrov AV, Demchuk AM, Saqqur M, Uchino K, Alvarez-Sabin J: Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke 2004; 35: 151-156. (Pubitemid 38057610)
5. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA stroke trial. Stroke 1997; 28: 2119-2125.
6. Mazighi M, Serfaty JM, Labreuche J, Laissy JP, Meseguer E, Lavallee PC, Cabrejo L, Slaoui T, Guidoux C, Lapergue B, Klein IF, Olivot JM, Abboud H, Simon O, Niclot P, Nifle C, Touboul PJ, Raphaeli G, Gohin C, Claeys ES, Amarenco P: Comparison of intravenous alteplase with a combined intravenous- endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol 2009; 8: 802-809.
7. Alexandrov AV, Burgin WS, Demchuk AM, El-Mitwalli A, Grotta JC: Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: sonographic classification and short-term improvement. Circulation 2001; 103: 2897-2902.
8. Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, Grotta JC: Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke. Stroke 2000; 31: 1812-1816.
9. Molina CA, Montaner J, Abilleira S, Arenillas JF, Ribo M, Huertas R, Romero F, Alvarez- Sabin J: Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke 2001; 32: 2821-2827.
10. Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, De Keyser J, Luijckx GJ: Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol 2008; 65: 607-611.
11. Schmülling S, Rudolf J, Strotmann-Tack T, Grond M, Schneweis S, Sobesky J, Thiel A, Heiss WD: Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis 2003; 16: 183-190.
12. Hallevi H, Grotta JC: Antiplatelet therapy and the risk of intracranial hemorrhage after intravenous tissue plasminogen activator therapy for acute ischemic stroke. Arch Neurol 2008; 65: 575-576.
13. Tanne D, Kasner SE, Demchuk AM, Koren- Morag N, Hanson S, Grond M, Levine SR: Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The Multicenter rt-PA Stroke Survey. Circulation 2002; 105: 1679-1685.
14. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saqqur M, Demchuk AM, Moye LA, Hill MD, Wojner AW: Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351: 2170-2178.
15. Demchuk AM, Christou I, Wein TH, Felberg RA, Malkoff M, Grotta JC, Alexandrov AV: Accuracy and criteria for localizing arterial occlusion with transcranial Doppler. J Neuroimaging 2000; 10: 1-12. (Pubitemid 30054400)
16. Burgin WS, Malkoff M, Felberg RA, Demchuk AM, Christou I, Grotta JC, Alexandrov AV: Transcranial Doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke. Stroke 2000; 31: 1128-1132.
17. Demchuk AM, Burgin WS, Christou I, Felberg RA, Barber PA, Hill MD, Alexandrov AV: Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001; 32: 89-93.
18. Zinkstok SM, Vermeulen M, Stam J, de Haan RJ, Roos YB: Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial. Cerebrovasc Dis 2010; 29: 79-81.
19. Álvarez-Sabín J, Huertas R, Quintana M, Rubiera M, Delgado P, Ribó M, Molina CA, Montaner J: Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke 2007; 38: 1076-1078.